全文获取类型
收费全文 | 81篇 |
免费 | 5篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 10篇 |
口腔科学 | 1篇 |
临床医学 | 12篇 |
内科学 | 7篇 |
皮肤病学 | 1篇 |
神经病学 | 8篇 |
特种医学 | 8篇 |
外科学 | 17篇 |
综合类 | 4篇 |
预防医学 | 2篇 |
眼科学 | 2篇 |
药学 | 5篇 |
中国医学 | 1篇 |
肿瘤学 | 6篇 |
出版年
2023年 | 7篇 |
2022年 | 24篇 |
2021年 | 8篇 |
2020年 | 7篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 3篇 |
2013年 | 1篇 |
2012年 | 6篇 |
2011年 | 1篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 1篇 |
2007年 | 1篇 |
2003年 | 1篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1991年 | 1篇 |
排序方式: 共有86条查询结果,搜索用时 15 毫秒
81.
Cold storage for organ preservation in kidney transplantation is a core predisposing factor for delayed graft function and the long-term outcome of transplanted kidneys. Hydroxysafflor yellow A (HSYA) is the most effective water-soluble active monomer in Safflower with a strong property of inhibiting hypoxia and reoxygenation (H/R). However, the evidence concerning the effect of HSYA on H/R in kidney transplantation is limited. To investigate whether HSYA has a protective effect on cold H/R injury,we investigated the possible protective mechanism. Here, we incubated HK-2 cells to establish a cold H/R model and observed HSYA activation in an in vitro model of cold-storage rewarming which included the cell survival rate, cell morphology and ultrastructure, protein expression of Bcl-2, Bax, CytC, Apaf-1, and caspase-3, and status of mitochondrial permeability transformation pores (MPTPs). Our data showed that HSYA pretreatment increased the survival rate of the cells, alleviated mitochondrial damage, decreased the expression of apoptosis-related proteins and inhibited the openness of mitochondrial permeability transformation pores. Our findings suggested that HSYA may be a major predisposing mediator of mitochondrial apoptosis and renal tubular injury in cold storage–associated transplantation and may be an effective therapeutic target for improving graft function and graft survival. 相似文献
82.
Zhao Dong MD PhD Kaiming Liu MD PhD Huanxian Liu MD Zhihua Jia MD Wei Gui MD Ming Dong MD PhD Yingying Cheng MD PhD Yudan Lv MD PhD Kang Qu MD Hongru Zhao MD Jianjun Chen MD Dan Zhang MD Zhiliang Fan MD PhD Xiaosu Yang MD Dongmei Hu MD Yanbo Zhang MD Hongyan Xie MD Mingxin Li MD PhD Bing Wen MD PhD Sufen Chen MD Peng Xu MD Qingqing Rong MD Qiu He MD PhD Zhanxiu Ren MD Fanhong Yan MD Heling Zhao MD Min Chen MD PhD Tingmin Yu MD Hongli Qu MD Xingkai An MD PhD Huailian Guo MD PhD Xinhua Zhang MD Xiaoping Pan MD Xiaojuan Wang MD PhD Shi Qiu MD Lvming Zhang MD Hongling Zhao MD Xin Pan MD Qi Wan MD Lanyun Yan MD Jing Liu MD Zhe Yu MD Mingjie Zhang MD Ye Ran MD Xun Han MD Shengyuan Yu MD PhD 《Headache》2023,63(1):62-70
83.
BackgroundHepatocellular carcinoma (HCC) is one of the most common malignant tumors that threaten human health; thus, the establishment of an animal model with clinical features similar to human hepatocellular carcinoma is of important practical significance.MethodsTaking advantage of the novel microcarrier-6, human HCC cells were injected into immunocompetent mice to establish a novel human HCC patient-derived xenograft (PDX) model. Primary HCC cells were isolated from fresh hepatocellular carcinoma tissues, which were subsequently co-cultured with microcarrier-6 to construct a three-dimensional tumor cell culture model in vitro. The HCC-microcarrier complex was implanted into mice by subcutaneous inoculation, and the tumor formation time, tumor formation rate, and pathological manifestation were recorded. Changes of immune parameters in mice were detected by flow cytometry.ResultsThe success rate was 60% (6/10) in the establishment of hepatocellular carcinoma PDX mouse model, and the total tumor formation rate of the tumor-forming model is 90–100%. H&E staining and immunohistochemical experiments indicate that the model well retained the characteristics of the primary tumor. Interestingly, M2 macrophages in tumor-bearing mice increased significantly, and the levels of CD4+ T cells were significantly reduced.ConclusionsThrough the application of the microcarrier-6 in immunocompetent mice, we successfully established a novel human HCC PDX model, which can be used to better study and further elucidate the occurrence and pathogenic mechanism of HCC, improve the predictability of toxicity and drug sensitivity in HCC. 相似文献
84.
ObjectiveTo determine the risk factors for acute rejection in liver transplantation and its impact on the outcomes of the recipients.MethodsClinicopathological data of 290 patients who underwent liver transplantation from January 2012 to December 2021 at our center were retrospectively evaluated. Patients were grouped into an acute rejection (AR) group and a normal (NM) group based on the confirmed histopathological diagnosis of acute rejection. Univariate and multivariate logistic regression were used to determine the risk factors for acute rejection.Results244 patients were included in the study. Acute rejection occurred in 27 (11.1%) of the patients. Warm ischemia time (P = 0.137), cold ischemia time (P = 0.064) and chronic liver failure (P = 0.001) were potential risk factors for acute rejection. Chronic liver failure (P < 0.001, OR = 8.22, 95% CI = 2.47–27.32) was the independent risk factor. There was no significant difference in overall survival between recipients with acute rejection and those without it (P = 0.985). The 1-, 3- and 5-year overall survival in the NM group was 98.1%, 85.7% and 78.6% respectively vs 88.9%, 82.5% and 82.5% respectively in the AR group.ConclusionAcute rejection does not appear to affect the long-term survival of the recipients. Only chronic liver failure was an independent risk factor for acute rejection. Our findings further illustrate that contradictions still exist on which factors influence acute rejection in liver transplant recipients.SummaryClinicopathological data of 290 liver transplant recipients at our center between January 2012 and December 2021 were retrospectively evaluated to determine the risk factors for acute rejection and its impact on the outcomes of the recipients. 244 patients were included in the analysis. 27 of the 244 experienced acute rejection. Propensity score matching was performed to reduce the confounding effect. Patients were assigned to an acute rejection group (n = 27) and a normal group (n = 54). Chronic liver failure (P < 0.001, OR = 8.22, 95% CI = 2.47–27.32) was the determined to be independent risk factor for acute rejection. Acute rejection did not appear to affect the long-term survival of the recipients and there was no significant difference in overall survival between the patients with acute rejection and those without it. 相似文献
85.
Advances in immune suppression therapies and desensitization have made possible kidney transplantation regardless of HLA incompatibility. Single antigen bead assay (SAB) is a semi-quantitative estimation of the amount of human leukocyte antigen (HLA) antibodies present in the recipient plasma, and mean fluorescence intensity (MFI) generated gives this rough estimation of the antibodies present in the recipient. Here we present a case of successful kidney transplantation in a patient who expressed DSA with high MFI. A 33-yr-old male, diagnosed with chronic kidney disease (CKD) on regular maintenance hemodialysis, opted for second kidney transplant with his sibling as prospective donor and was referred to the department of Transplant Immunology for histocompatibility testing. Patient had HLA incompatibility with multiple DSA identified by SAB. Patient undergone 20 sessions of plasma exchange till discharge and finally till 6 months graft was functioning well. The authors thus conclude that the option of a high-risk HLA incompatible kidney transplant can be offered to recipients with high MFI DSA, who wish to undergo transplantation for end stage renal disease. 相似文献
86.